Literature DB >> 10694760

QALYs and ageism: philosophical theories and age weighting.

A Tsuchiya1.   

Abstract

QALY maximization is sometimes criticized for being 'ageist', because, other things being equal, the elderly, with a shorter life expectancy, will be given lower priority. On the other hand, there are philosophical arguments that, for different reasons, advocate rationing health care to the elderly, even when the size of the expected benefits in QALY terms is the same across older and younger patients. This paper examines six proposals, both from the philosophical and the health economics literature, that will lead to such conclusions. These are: two variants of the so-called fair innings argument, the fair innings weights, the Disability Adjusted Life Year (DALY) age weighting, the biographical life span, and the prudential lifetime account. Two questions are addressed with regard to each of these. First, what is the reason for choosing the younger patient when the QALY gains are equal; second, will the younger patient continue to be chosen even when the QALY gains to the older patient are larger. The paper studies the relationship between the six proposals and explores their possible implications for QALY maximization. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2000        PMID: 10694760     DOI: 10.1002/(sici)1099-1050(200001)9:1<57::aid-hec484>3.0.co;2-n

Source DB:  PubMed          Journal:  Health Econ        ISSN: 1057-9230            Impact factor:   3.046


  13 in total

1.  "Primary" rationing of health services in ageing societies--a normative analysis.

Authors:  Friedrich Breyer; Carlo Schultheiss
Journal:  Int J Health Care Finance Econ       Date:  2002-11

Review 2.  Resource allocation, social values and the QALY: a review of the debate and empirical evidence.

Authors:  David L B Schwappach
Journal:  Health Expect       Date:  2002-09       Impact factor: 3.377

3.  Ethical issues in geriatric medicine: a unique problematic?

Authors:  Eike-Henner W Kluge
Journal:  Health Care Anal       Date:  2002

4.  What is the value of oncology medicines?

Authors:  Joshua Cohen; William Looney
Journal:  Nat Biotechnol       Date:  2010-11       Impact factor: 54.908

5.  Novel approaches to incorporating pharmacoeconomic studies into phase III clinical trials for Alzheimer's disease.

Authors:  H Fillit; J Cummings; P Neumann; T McLaughlin; P Salavtore; C Leibman
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 6.  Capabilities and health.

Authors:  P Anand
Journal:  J Med Ethics       Date:  2005-05       Impact factor: 2.903

7.  A framework for measuring health inequity.

Authors:  Yukiko Asada
Journal:  J Epidemiol Community Health       Date:  2005-08       Impact factor: 3.710

Review 8.  Incorporating process utility into quality adjusted life years: a systematic review of empirical studies.

Authors:  Victoria K Brennan; Simon Dixon
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

9.  Health benefits of reduced patient cost sharing in Japan.

Authors:  Akihiro Nishi; J Michael McWilliams; Haruko Noguchi; Hideki Hashimoto; Nanako Tamiya; Ichiro Kawachi
Journal:  Bull World Health Organ       Date:  2012-02-12       Impact factor: 9.408

10.  Priority setting and patient adaptation to disability and illness: outcomes of a qualitative study.

Authors:  John McKie; Rosalind Hurworth; Bradley Shrimpton; Jeff Richardson; Catherine Bell
Journal:  Health Care Anal       Date:  2014-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.